Capecitabine (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Capecitabine" in English language version.

refsWebsite

Global rank English rank

9web.archive.org

1^st place

6nih.gov

4^th place

4doi.org

2^nd place

2europa.eu

68^th place

117^th place

2fda.gov

447^th place

338^th place

2medicines.org.uk

3,823^rd place

2,387^th place

1wikipathways.org

low place

1drugs.com

399^th place

333^rd place

1books.google.com

3^rd place

1handle.net

102^nd place

76^th place

1tga.gov.au

3,984^th place

2,622^nd place

1pharmaceutical-journal.com

low place

1medscape.com

719^th place

636^th place

1worldcat.org

5^th place

books.google.com

Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 511. ISBN 9783527607495. Archived from the original on 12 January 2023. Retrieved 30 August 2017.

doi.org

Caudle KE, Thorn CF, Klein TE, Swen JJ, McLeod HL, Diasio RB, et al. (December 2013). "Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing". Clinical Pharmacology and Therapeutics. 94 (6): 640–645. doi:10.1038/clpt.2013.172. PMC 3831181. PMID 23988873.
Koo K, Pasternak AL, Henry NL, Sahai V, Hertz DL (June 2022). "Survey of US Medical Oncologists' Practices and Beliefs Regarding DPYD Testing Before Fluoropyrimidine Chemotherapy". JCO Oncology Practice. 18 (6): e958 – e965. doi:10.1200/OP.21.00874. PMC 9191302. PMID 35239419.
Amstutz U, Froehlich TK, Largiadèr CR (September 2011). "Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity". Pharmacogenomics. 12 (9): 1321–1336. doi:10.2217/pgs.11.72. PMID 21919607.
Ma WW, Saif WM, Cartwright TH, Fakih M, El-Rayes BF, King T, et al. (20 May 2016). "Uridine triacetate as a lifesaving antidote for overdoses and severe early-onset 5-fluorouracil and capecitabine toxicities". Journal of Clinical Oncology. 34 (15_suppl): e21689 – e21689. doi:10.1200/JCO.2016.34.15_suppl.e21689. ISSN 0732-183X.

drugs.com

"Capecitabine". The American Society of Health-System Pharmacists. Archived from the original on 15 April 2016. Retrieved 8 December 2016.

europa.eu

ema.europa.eu

"Xeloda EPAR". European Medicines Agency. 2 February 2001. Retrieved 2 July 2024.
"Capecitabine Teva : EPAR – Product Information" (PDF). European Medicines Agency. Teva Pharma B.V. 10 January 2014. Archived (PDF) from the original on 4 February 2014. Retrieved 25 January 2014.

fda.gov

"FDA approves updated drug labeling including new indications and dosing regimens for capecitabine tablets under Project Renewal". U.S. Food and Drug Administration. 15 December 2022. Archived from the original on 27 January 2023. Retrieved 26 January 2023. This article incorporates text from this source, which is in the public domain.
"FDA approves updated drug labeling including new indications". U.S. Food and Drug Administration. 1 October 2024. Archived from the original on 16 December 2022. Retrieved 5 January 2025.

handle.net

hdl.handle.net

World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

medicines.org.uk

"Capecitabine 150mg – Summary of Product Characteristics (SPC)". electronic Medicines Compendium. Zentiva. 23 December 2013. Archived from the original on 1 February 2014. Retrieved 25 January 2014.
ATC code (23 April 2021). "Summary of Product Characteristics (SmPC)". (emc). Retrieved 5 January 2025.

medscape.com

reference.medscape.com

"Xeloda (capecitabine) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. 25 January 2014. Archived from the original on 2 February 2014.

nih.gov

pubmed.ncbi.nlm.nih.gov

Caudle KE, Thorn CF, Klein TE, Swen JJ, McLeod HL, Diasio RB, et al. (December 2013). "Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing". Clinical Pharmacology and Therapeutics. 94 (6): 640–645. doi:10.1038/clpt.2013.172. PMC 3831181. PMID 23988873.
Koo K, Pasternak AL, Henry NL, Sahai V, Hertz DL (June 2022). "Survey of US Medical Oncologists' Practices and Beliefs Regarding DPYD Testing Before Fluoropyrimidine Chemotherapy". JCO Oncology Practice. 18 (6): e958 – e965. doi:10.1200/OP.21.00874. PMC 9191302. PMID 35239419.
Amstutz U, Froehlich TK, Largiadèr CR (September 2011). "Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity". Pharmacogenomics. 12 (9): 1321–1336. doi:10.2217/pgs.11.72. PMID 21919607.

ncbi.nlm.nih.gov

Caudle KE, Thorn CF, Klein TE, Swen JJ, McLeod HL, Diasio RB, et al. (December 2013). "Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing". Clinical Pharmacology and Therapeutics. 94 (6): 640–645. doi:10.1038/clpt.2013.172. PMC 3831181. PMID 23988873.
Koo K, Pasternak AL, Henry NL, Sahai V, Hertz DL (June 2022). "Survey of US Medical Oncologists' Practices and Beliefs Regarding DPYD Testing Before Fluoropyrimidine Chemotherapy". JCO Oncology Practice. 18 (6): e958 – e965. doi:10.1200/OP.21.00874. PMC 9191302. PMID 35239419.

dailymed.nlm.nih.gov

"XELODA (capecitabine) tablet, film coated [Genentech, Inc.]". DailyMed. Genentech, Inc. December 2013. Archived from the original on 1 February 2014. Retrieved 25 January 2014.

pharmaceutical-journal.com

Robinson J (5 May 2022). "Cancer pharmacogenomics testing: are we hitting the mark?". The Pharmaceutical Journal. Retrieved 26 December 2024.

tga.gov.au

ebs.tga.gov.au

"NAME OF THE MEDICINE XELODA® Capecitabine" (PDF). TGA eBusiness Services. Roche Products Pty Limited. 5 December 2013. Archived from the original on 11 September 2017. Retrieved 25 January 2014.

web.archive.org

"Capecitabine". The American Society of Health-System Pharmacists. Archived from the original on 15 April 2016. Retrieved 8 December 2016.
Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 511. ISBN 9783527607495. Archived from the original on 12 January 2023. Retrieved 30 August 2017.
"FDA approves updated drug labeling including new indications and dosing regimens for capecitabine tablets under Project Renewal". U.S. Food and Drug Administration. 15 December 2022. Archived from the original on 27 January 2023. Retrieved 26 January 2023. This article incorporates text from this source, which is in the public domain.
"XELODA (capecitabine) tablet, film coated [Genentech, Inc.]". DailyMed. Genentech, Inc. December 2013. Archived from the original on 1 February 2014. Retrieved 25 January 2014.
"Capecitabine Teva : EPAR – Product Information" (PDF). European Medicines Agency. Teva Pharma B.V. 10 January 2014. Archived (PDF) from the original on 4 February 2014. Retrieved 25 January 2014.
"Capecitabine 150mg – Summary of Product Characteristics (SPC)". electronic Medicines Compendium. Zentiva. 23 December 2013. Archived from the original on 1 February 2014. Retrieved 25 January 2014.
"NAME OF THE MEDICINE XELODA® Capecitabine" (PDF). TGA eBusiness Services. Roche Products Pty Limited. 5 December 2013. Archived from the original on 11 September 2017. Retrieved 25 January 2014.
"FDA approves updated drug labeling including new indications". U.S. Food and Drug Administration. 1 October 2024. Archived from the original on 16 December 2022. Retrieved 5 January 2025.
"Xeloda (capecitabine) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. 25 January 2014. Archived from the original on 2 February 2014.

wikipathways.org

The interactive pathway map can be edited at WikiPathways: "FluoropyrimidineActivity_WP1601".

worldcat.org

search.worldcat.org

Ma WW, Saif WM, Cartwright TH, Fakih M, El-Rayes BF, King T, et al. (20 May 2016). "Uridine triacetate as a lifesaving antidote for overdoses and severe early-onset 5-fluorouracil and capecitabine toxicities". Journal of Clinical Oncology. 34 (15_suppl): e21689 – e21689. doi:10.1200/JCO.2016.34.15_suppl.e21689. ISSN 0732-183X.